Home    Back

Solifenacin    (DrugBank: Solifenacin)

2 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease3
13Multiple sclerosis/Neuromyelitis optica1

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 2,123 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03149809
(ClinicalTrials.gov)		March 1, 20189/5/2017Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson DiseaseBehavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson DiseaseOveractive Bladder;Parkinson DiseaseDrug: solifenacin;Behavioral: Pelvic floor muscle exercise-based behavioral therapyVA Office of Research and DevelopmentNULLRecruitingN/AN/AAll90Phase 3United States
2NCT01018264
(ClinicalTrials.gov)		January 201019/11/2009Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's DiseaseURGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's DiseaseOveractive Bladder in Parkinson's DiseaseDrug: solifenacin succinate (VESIcare);Drug: placeboUniversity of South FloridaNULLCompleted40 Years80 YearsAll23Phase 4United States
3NCT00584090
(ClinicalTrials.gov)		November 200721/12/2007Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's DiseaseUrinary Incontinence;Parkinson's DiseaseDrug: Solifenacin Succinate (VESIcare);Drug: PlaceboUniversity of South FloridaNULLWithdrawn30 Years80 YearsBoth0Phase 4United States

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3,050 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00629642
(ClinicalTrials.gov)		March 14, 200826/2/2008Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple SclerosisA Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor OveractivityMultiple Sclerosis;Neurogenic Bladder;Spinal Cord DiseasesDrug: Solifenacin Succinate;Drug: Oxybutynin Hydrochloride;Drug: PlaceboAstellas Pharma IncNULLCompleted18 Years65 YearsAll249Phase 4Australia;Belgium;Czechia;France;Germany;Hungary;Italy;Netherlands;Russian Federation;Spain;United Kingdom;Czech Republic;Portugal